Geography once drove disparity, but access now hinges on how effectively centers can employ modern donor-utilization tools.

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most ...

Both CV mortality and major bleeding were rarer when antiplatelets weren’t added, with no tradeoff in ischemic events.

The study of LAAO cases provides physicians with evidence they can cite when requesting tools for additional protection.

Final follow-up from the trial shows durable protection against TLF, especially in chronic total occlusions and diffuse long ...

For primary prevention patients at high risk, such as those with a 10-year risk > 10%, the LDL target is less than 70 mg/dL (class 2a recommendation). For this group, treatment begins with a ...

The study emphasizes the importance of vigilance with diet and exercise, among other things, to reduce CV risk in type 2 diabetes.

Operative mortality fell over time, but there was a concerning uptick in recent years attributed to low-volume sites.

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

In hypothetical situations, physicians chose intensive treatment more often if BP and mobility metrics were available.

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

PE or PEERLESS, the choice of therapy was shifting, influenced by patient factors and institutional protocols.